O-Isopropyl-syn-benzaldoxim | 10229-57-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-Isopropyl-syn-benzaldoxim
• 英文别名: Benzaldehyde, O-isopropyloxime；(E)-1-phenyl-N-propan-2-yloxymethanimine
• CAS: 10229-57-9
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: RUOIJKWFWWUJTP-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pyrimidine compounds and their use
  申请人：Mizuno Hajime

  公开号：US20050107609A1

  公开（公告）日：2005-05-19

  Pyrimidine compounds of formula (1): wherein R 1 is C 3 -C 7 alkynyl optionally substituted with halogen; R 2 and R 3 are independently hydrogen or the like; and R 4 is C 3 -C 7 alkynyloxy optionally substituted with halogen, optionally substituted phenyl, or the like have an excellent pesticidal effect.

  式（1）的嘧啶化合物： 其中，R1是C3-C7炔基，可选地被卤素取代； R2和R3独立地是氢或类似物； R4是C3-C7炔氧基，可选地被卤素、可选地被取代的苯基或类似物取代，具有优异的杀虫效果。
• DNA polymerase beta inhibitors
  申请人：The Johns Hopkins University

  公开号：US10711027B2

  公开（公告）日：2020-07-14

  Methods and compounds are disclosed for irreversibly inhibiting a DNA repair enzyme that possesses lyase activity.

  本研究公开了不可逆地抑制具有裂解酶活性的 DNA 修复酶的方法和化合物。
• PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP1366026B1

  公开（公告）日：2004-12-01
• SYSTEM AND METHOD FOR DETERMINING ONSET AND DISEASE PROGRESSION
  申请人：Respiration Scan Ltd

  公开号：EP4013302A1

  公开（公告）日：2022-06-22
• ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080125444A1

  公开（公告）日：2008-05-29

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.